Referenzen
Produkte Transfektion
Kostenlose Testsamples
Anwendungshinweise:
Im „Transfection Reagent Selection Guide“ können Sie durch Filterfunktionen z.B. für Ihre Kombination aus zu transfizierender Zelle und Nukleinsäure die Liste vorhandener Referenzen durchsuchen. Ebenso können Sie im Feld „Referenzen durchsuchen“ am Anfang der Seite mit passenden Schlagwörtern zu einem Ergebnis gelangen. Eine Referenz zeigt an, dass das gefundene Transfektionsreagenz bereits erfolgreich für die entsprechende Anwendung verwendet wurde. Im Idealfall sind getestete Transfektionsparameter und Transfektionseffizienzen angegeben.
Keine Referenz? > Allgemeine Auswahlhilfe
Wenn Sie keine Referenz gefunden haben, heißt das nicht, dass kein passendes Reagenz zur Verfügung steht, sondern lediglich, dass bisher keine Erfahrungsberichte vorliegen. In diesem Falle kann durch eine Vorauswahl ein erfolgsversprechendes Transfektionsreagenz ausgewählt (Allgemeine Auswahlhilfe) und letztendlich ausgetestet (Kostenlose Testsamples) werden. Wenn Sie einen Erfahrungsbericht für uns schreiben möchten machen wir Ihnen ein Angebot für eine Gegenleistung.
CELL TYPE | DESCRIPTION OF CELL TYPE | CAT.NO. | SPECIES | ORIGIN OF CELLS | COMMON CELL TYPE | GROWTH PROPERTIES | NUCLEIC ACID / DELIVERED MOLECULE | APPLICATION | PRODUCT | REFERENCE TYPE | BIBLIOGRAPHIC DATA | LINK | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | E. M. Lynes et al., J. Cell Sci., Sep 2013; 126: 3893 - 3903 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | S. Duvezin-Caubet et al., J. Biol. Chem., Dec 2006; 281: 37972 - 37979. | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | plasmid | Metafectene | publication | F. J. Martínez-Sanz et al., Europ. J. of Med. Chem., 2016, 109: 114-123; doi.org/10.1016/j.ejmech.2015.12.043 | ||||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | C. T. Hellwig et al., J. Biol. Chem., Aug 2008; 283: 21676 - 21685 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | stable transfection | Metafectene PRO | publication | M. De Luca et al., J. Cell Sci., Jun 2014; 127: 2697 - 2708 | Link | |
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | I. Sargiannidou et al., Neurogenetics, 2015, DOI 10.1007/s10048-015-0442-4 | |||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | B. Blumenthal et al., Infect. Immun., Jul 2007; 75: 3344 - 3353 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | E. Echeverria et al., Life Sciences, 2019, 239, 116872, doi.org/10.1016/j.lfs.2019.116872 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | L. Silvestri et al., Hum. Mol. Genet., Nov 2005; 14: 3477 - 3492 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene PRO | publication | M. R. Spinosa et al., J. Neurosci., Feb 2008; 28: 1640 - 1648 | Link | ||
HeLa |
Human cervix adenocarcinoma cell line | ATCC CCL-2 | Human | genital tract | cell line | adherent | plasmid | Metafectene FluoR | publication | J. E. Alford et al., PLoS ONE, 2014, 9(3): e91429, doi:10.1371/journal.pone.0091429 | Link | ||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2003; 77: 10548 - 10556 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | J. Münch et al., J. Virol., Aug 2005, 79 (16), 10547-10560 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | F. Kirchhoff et al., J. Virol., Jul 2004; 78: 6864 - 6874. | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Brenner et al., J. Virol., May 2006; 80: 4469 - 4481 | Link | |||
HeLa CIITA |
Human cervix adenocarcinoma cell line, stably expressing the MHC class II transactivator CIITA | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | M. Schindler et al., J. Virol., Oct 2004; 78: 10588 - 10597 | Link | |||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | ATCC CCL-2.1 | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | application note | ![]() |
|||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | D. Kaul et al., Blood Cells, Molecules and Diseases, 2015, 55: 89-93, doi.org/10.1016/j.bcmd.2015.05.001 | ||||
HeLa-229 |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | K2 Transfection System | publication | A. Garg et al., Blood Cells, Molecules and Diseases, 2015, 55: 248-254, doi.org/10.1016/j.bcmd.2015.07.009 | ||||
HeLa-ABCA1-GFP |
Human cervix adenocarcinoma cell line (derivat of HeLa) | Human | genital tract | cell line | adherent | plasmid | Metafectene | publication | N. Mukhamedova et al., Methods Mol. Biol., 2016 ; 1354: 281-292; doi:10.1007/978-1-4939-3046-3_19 | ||||
HeLa-DR-13–9 |
Human cervix adenocarcinoma cell line (derivative of HeLa) | Human | genital tract | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | B. Haynesa et al., Biochim Biophys Acta Mol Basis Dis., 2020,1866(1): 165561, doi:10.1016/j.bbadis | Link | ||
HeLa-S3 |
Human cervix carcinoma cell line (subclone) | ATCC CCL-2.2 | Human | genital tract | cell line | adherent | plasmid | Metafectene | application note | ![]() |
|||
HeLa-T4 |
Human cervix carcinoma cell line susceptible to HIV-1 infection (Derivat of HeLa ) | Human | genital tract | cell line | suspension | plasmid | Metafectene | publication | D. Wilflingseder et al., J. Immunol., Jun 2007; 178: 7840 - 7848 | Link | |||
HEp-2 |
Human carcinoma cell line (HeLa contaminant) | ATCC CCL-23 | Human | unknown | cell line | adherent | plasmid | RNA-Interference | Metafectene | publication | H. Chi et al., Lin Chuang Er Bi Yan Hou Ke Za Zhi, Nov 2005; 19(21): 992-5 | ||
HEp-2 |
Human carcinoma cell line (HeLa contaminant) | ATCC CCL-23 | Human | unknown | cell line | adherent | plasmid | Metafectene PRO | publication | R. S. Cruz Cosme et al., J. Virol., Apr 2009; 83: 2839 - 2850 | Link |